Atypical fractures: An issue of concern or a myth?

被引：9

作者：

Al-Ashqar, Mohammad ^{[1
]}

Panteli, Michalis ^{[2
]}

Chakrabarty, Gautam ^{[3
]}

Giannoudis, Peter V. ^{[2
]}

机构：

[1] Leeds Gen Infirm, Dept Trauma & Orthopaed, Leeds, W Yorkshire, England

[2] Univ Leeds, Sch Med, Acad Dept Trauma & Orthopaed, Clarendon Wing,Level A,Great George St, Leeds LS1 3EX, W Yorkshire, England

[3] Univ Huddersfield, Dept Trauma & Orthopaed, Huddersfield Royal Infirm, Huddersfield, W Yorkshire, England

来源：

INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED | 2018年 / 49卷 / 03期

关键词：

Atypical; Osteoporosis; Stress/insufficiency fractures; Bisphosphonates; SUBTROCHANTERIC STRESS-FRACTURES; SUPPRESSED BONE TURNOVER; FEMORAL-SHAFT FRACTURES; POSTMENOPAUSAL WOMEN; IN-VITRO; BISPHOSPHONATE USE; SALMON-CALCITONIN; OSTEOPOROSIS; RISK; ALENDRONATE;

D O I：

10.1016/j.injury.2017.12.016

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Atypical Femoral Fractures (AFF) represent fractures located between the lesser trochanter and the supracondylar flare of a femur. An increasing pool of evidence supports their association with the prolonged use of bisphosphonates, even though a direct correlation is yet to be proved. The purpose of this review is to encapsulate the current evidence associating bisphosphonate use and the development of AFFs, the clinical features related to their presentation, as well as to report the armamentarium of strategies available in the prevention and treatment of AFFs. Based on these evidence, we propose a management algorithm for AFFs, that can serve as a guide for patients presenting with this condition. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：649 / 655

页数：7

共 50 条

[31] Factors affecting healing and progression of conservatively treated incomplete atypical femoral fractures: retrospective observational study
Png, Meng Ai
Koh, Joyce Suang Bee
Mohan, P. Chandra
Howe, Choong Yin
Howe, Tet Sen
JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (01) : 61 - 73
[32] Atypical Fractures Following Bisphosphonate Therapy
Patel, Rati N.
Ashraf, Anwar
Sundaram, Murali
SEMINARS IN MUSCULOSKELETAL RADIOLOGY, 2016, 20 (04) : 376 - 381
[33] Bisphosphonates and atypical subtrochanteric fractures of the femur
Kharwadkar, N.
Mayne, B.
Lawrence, J. E.
Khanduja, V.
BONE & JOINT RESEARCH, 2017, 6 (03): : 144 - 153
[34] Bisphosphonates and the risk of atypical femur fractures
Black, Dennis M.
Condra, Katherine
Adams, Annette L.
Eastell, Richard
BONE, 2022, 156
[35] Atypical subtrochanteric fractures after long-term bisphosphonate therapy
Czerwinski, Edward
ENDOKRYNOLOGIA POLSKA, 2011, 62 (01) : 84 - 87
[36] Prodromal Symptoms in Patients with Bisphosphonate-Associated Atypical Fractures of the Femur
Kharazmi, Mohammad
Michaelsson, Karl
Hallberg, Par
JOURNAL OF BONE AND MINERAL METABOLISM, 2015, 33 (05) : 516 - 522
[37] Atypical femoral fractures related to bisphosphonate use: A comprehensive review of 19 patients
Sahin, Koray
Ergin, Omer Naci
Bayram, Serkan
Akgul, Turgut
ULUSAL TRAVMA VE ACIL CERRAHI DERGISI-TURKISH JOURNAL OF TRAUMA & EMERGENCY SURGERY, 2019, 25 (06): : 603 - 610
[38] Atypical fractures do not have a thicker cortex
Koeppen, V. A.
Schilcher, J.
Aspenberg, P.
OSTEOPOROSIS INTERNATIONAL, 2012, 23 (12) : 2893 - 2896
[39] Disentangling the Emerging Evidence around Atypical Fractures
Abrahamsen, Bo
Clark, Emma M.
CURRENT RHEUMATOLOGY REPORTS, 2012, 14 (03) : 212 - 216
[40] Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures
Ahn, Joosuk
Kim, Chul-Ho
Kim, Ji Wan
SCIENTIFIC REPORTS, 2024, 14 (01):

← 1 2 3 4 5 →